Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 15/20 | 0.55 |
| ▸ | NOS3 | P29474 | 11/20 | 0.55 |
| ▸ | NOS1 | P29475 | 11/20 | 0.55 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.49 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3864843 | 1.00 | NOS2 (0.55) | NOS2NOS3NOS1TAS1R3TAS1R1 | |
| SCHEMBL8194922 | 0.88 | NOS2 (0.45) | NOS2NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL3861171 | 0.87 | NOS2 (0.44) | NOS2NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL3861175 | 0.87 | NOS2 (0.44) | NOS2NOS3NOS1 | |
| SCHEMBL28346059 | 0.79 | NOS2 (0.64) | NOS2NOS3NOS1CNR2 | |
| SCHEMBL29323985 | 0.74 | PTGS2 (0.45) | — | |
| SCHEMBL14675695 | 0.71 | PTGS2 (0.50) | — | |
| SCHEMBL14675696 | 0.71 | PTGS2 (0.50) | — | |
| SCHEMBL31414614 | 0.71 | NOS2 (0.56) | NOS2NOS3NOS1TAS1R3TAS1R1 | |
| SCHEMBL6960203 | 0.71 | TTR (0.63) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2134703-A1 | AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | Neuromed Pharmaceuticals, Ltd. (CA) | 2009-12-23 | — | — | EP | disclosed |
| US-20080227823-A1 | (E)-4-(3-(3-bromo-4-fluorophenyl)acrylamido)-N-(2-(5-fluoro-1H-indol-3-yl)ethyl)piperidine-4-carboxamide; ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted T-type calcium channel activity | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-09-18 | — | — | US | disclosed |
| US-20080227823-A1 | (E)-4-(3-(3-bromo-4-fluorophenyl)acrylamido)-N-(2-(5-fluoro-1H-indol-3-yl)ethyl)piperidine-4-carboxamide; ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted T-type calcium channel activity | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-09-18 | — | — | US | disclosed |
| US-20080227823-A1 | (E)-4-(3-(3-bromo-4-fluorophenyl)acrylamido)-N-(2-(5-fluoro-1H-indol-3-yl)ethyl)piperidine-4-carboxamide; ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted T-type calcium channel activity | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-09-18 | — | — | US | disclosed |
| WO-2008110008-A1 | AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008110008-A1 | AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227823-A1 | (E)-4-(3-(3-bromo-4-fluorophenyl)acrylamido)-N-(2-(5-fluoro-1H-indol-3-yl)ethyl)piperidine-4-carboxamide; ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted T-type calcium channel activity | CACNA1G, KCNN4, CACNA1E | NOS2 2888/4885NOS3 3223/4885NOS1 2956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.